drugset / Trial / NCT05345769
Safety and Efficacy of AM712 in Patients with NAMD
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with neovascular age- related macular degeneration (nAMD).
Timeline
- Start
- 2022-04-28
- Primary completion
- 2024-11-04
- Completion
- 2024-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AM712 | Protein / enzyme biologic | — | Intravitreal |